SCHEMBL308728

SCHEMBL308728

COc1cc(-c2cc3nccc(Oc4ccc(N)cc4F)c3s2)ccc1OCCN1CCOCC1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AXL P30530 6/20 0.64
MCHR1 Q99705 5/20 0.49
MET P08581 8/20 0.46
MST1R Q04912 4/20 0.44
EGFR P00533 3/20 0.44
HGF P14210 2/20 0.44
RPS6KB1 P23443 2/20 0.44
FLT4 P35916 2/20 0.44
KDR P35968 2/20 0.44
TEK Q02763 2/20 0.44
BTK Q06187 2/20 0.44
AURKA O14965 1/20 0.44
LCK P06239 1/20 0.44
CSF1R P07333 1/20 0.44
JAK2 O60674 1/20 0.44
FLT1 P17948 1/20 0.44
FGFR2 P21802 1/20 0.44
FLT3 P36888 1/20 0.44
SRC P12931 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10224017 0.91 AXL (0.56) AXLMCHR1METMST1RKDR
SCHEMBL305946 0.87 MCHR1 (0.53) AXLMCHR1METMST1REGFR
SCHEMBL3576981 0.87 AXL (0.52) AXLMETMST1RKDRBTK
SCHEMBL13166733 0.83 KDR (0.52) AXLMETMST1REGFRKDR
SCHEMBL308501 0.83 MST1R (0.53) AXLMETMST1REGFRRPS6KB1
SCHEMBL14289192 0.82 AXL (0.92) AXLMETMST1REGFRHGF
SCHEMBL29908856 0.82 AXL (0.92) AXLMETMST1REGFRHGF
SCHEMBL1591152 0.82 AXL (0.92) AXLMETMST1REGFRHGF
SCHEMBL308965 0.80 AXL (0.49) AXLMETMST1RKDR
SCHEMBL3566450 0.79 MET (0.69) METKDRAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329726-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-12-11 US disclosed
US-20120083482-A1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE INC. 2012-04-05 US disclosed
US-8093264-B2 Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-01-10 US disclosed
US-8093264-B2 Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-01-10 US disclosed
US-8093264-B2 Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-01-10 US disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling HGF, MET, FLT1 AXL 370/4885MCHR1 377/4885MET 2/4885
US-20120083482-A1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING HGF, MET, KDR AXL 184/4885MCHR1 158/4885MET 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.